Preexisting High Cholesterol in Pregnancy Linked to Elevated CV Risk
Researchers urge clinicians to integrate lipid management into prenatal care to mitigate elevated obstetric complications and cardiovascular risks.
Researchers urge clinicians to integrate lipid management into prenatal care to mitigate elevated obstetric complications and cardiovascular risks.
Labs should consider self-reported race when screening for open neural tube defects to improve prenatal care equity for Black individuals.
Devyser Compact is a rapid genetic test for prenatal chromosome testing and is approved under the new more comprehensive regulation.
The FDA is warning the public of the risk of false results, inappropriate use, and inappropriate interpretation of results with NIPS tests.
Read MoreSema4 and Mount Sinai collaborated on two studies that demonstrate how machine learning can be used to improve postpartum hemorrhage risk prediction.
Read MoreResearchers have developed a testing device that may help advance diagnosis and treatment of preterm birth.
Read MoreVeritas has created a new prenatal diagnostic test that can help identify fetal anomalies in at-risk pregnancies.
Read MoreResearchers have identified biological markers that could improve blood tests of pregnant women to detect risks of pregnancy complications earlier.
Read MoreBioFluidica, a privately held biotechnology company, plans to commercialize its LiquidScan Automated Liquid Biopsy System.Â
Read MoreSema4 Elements, a portfolio of information-driven genomic reproductive health solutions that enable providers to treat patients holistically, has launched.
Read MoreHalf of pregnant women who had a simple blood test to check their iron stores had low iron levels; one in four had severe iron deficiency.
Read MoreBioReference Laboratories, Inc. has acquired the U.S. Ariosa centralized laboratory prenatal testing business from Roche.
Read MoreAs part of the agreement, EchelonDx is providing expertise using its precise PrenatalDx technology to help enhance the data analysis and reporting capabilities for Cradle’s comprehensive fetal genetic analysis and health screening solutions.
Read MoreOffering insurance coverage of non-invasive prenatal testing to all pregnant women increases utlilization at a cost of less than 3 cents per member per month.
Read MoreThe method uses a DNA biomarker to easily screen pregnant women for harmful prenatal environmental contaminants like air pollution linked to childhood illness and developmental disorders.
Read MoreThe new CPT PLA code will facilitate billing and payment for the PreTRM Test, the company’s proprietary proteomic blood test for measuring a woman’s risk of spontaneous preterm birth to enable timely intervention.
Read MoreThe PRIME study is designed to provide a blueprint for how healthcare can more effectively identify and manage high-risk pregnancies and reduce preterm birth.
Read MoreA new study outlines a role for pregnancy-associated plasma protein A in gestational diabetes, with potential as a diagnostic tool and therapeutic target.
Read More